159 related articles for article (PubMed ID: 7553681)
1. The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer.
Brotherick I; Shenton BK; Cowan WK; Angus B; Horne CH; Higgs MJ; Lennard TW
Cancer Immunol Immunother; 1995 Sep; 41(3):137-45. PubMed ID: 7553681
[TBL] [Abstract][Full Text] [Related]
2. p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer.
Brotherick I; Shenton BK; Cowan WK; Angus B; Horne CH; Higgs MJ; Lennard TW
Cancer Immunol Immunother; 1995 Sep; 41(3):146-50. PubMed ID: 7553682
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma.
Erdem O; Dursun A; Coşkun U; Günel N
Tumori; 2005; 91(1):46-52. PubMed ID: 15850004
[TBL] [Abstract][Full Text] [Related]
4. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
5. Two-color, cytokeratin-labeled dna flow cytometric analysis of 332 breast cancers: lack of prognostic value with 12-year follow-up.
Prasad AR; Divine G; Zarbo RJ
Arch Pathol Lab Med; 2001 Mar; 125(3):364-74. PubMed ID: 11231485
[TBL] [Abstract][Full Text] [Related]
6. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
Leal CB; Schmitt FC; Bento MJ; Maia NC; Lopes CS
Cancer; 1995 Apr; 75(8):2123-31. PubMed ID: 7697603
[TBL] [Abstract][Full Text] [Related]
7. Predicting outcome for patients with node negative breast cancer: a comparative study of the value of flow cytometry and cell image analysis for determination of DNA ploidy.
Yuan J; Hennessy C; Givan AL; Corbett IP; Henry JA; Sherbet GV; Lennard TW
Br J Cancer; 1992 Mar; 65(3):461-5. PubMed ID: 1348424
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
[TBL] [Abstract][Full Text] [Related]
9. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F
J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034
[TBL] [Abstract][Full Text] [Related]
10. Can we identify the group of small invasive (T1a,b) breast cancers with minimal risk of axillary lymph node involvement? A pathohistological and DNA flow cytometric study.
Bezić J; Samija-Projić I; Projić P; Ljubković J; Capkun V; Tomić S
Pathol Res Pract; 2011 Jul; 207(7):438-42. PubMed ID: 21689895
[TBL] [Abstract][Full Text] [Related]
11. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.
Pinto AE; André S; Pereira T; Nóbrega S; Soares J
Ann Oncol; 2001 Apr; 12(4):525-33. PubMed ID: 11398888
[TBL] [Abstract][Full Text] [Related]
12. Mutual predictive value of c-erbB-2 overexpression and various prognostic factors in ductal invasive breast carcinoma.
Jakić-Razumović J; Petrovecki M; Uzarević B; Gamulin S
Tumori; 2000; 86(1):30-6. PubMed ID: 10778763
[TBL] [Abstract][Full Text] [Related]
13. Internal mammary nodal status is a more reliable prognostic factor than DNA ploidy and c-erb B-2 expression in patients with breast cancer.
Noguchi M; Koyasaki N; Ohta N; Kitagawa H; Earashi M; Thomas M; Miyazaki I; Mizukami Y
Arch Surg; 1993 Feb; 128(2):242-6. PubMed ID: 8094282
[TBL] [Abstract][Full Text] [Related]
14. DNA flow cytometry but not telomerase activity as predictor of disease-free survival in pT1-2/N0/G2 breast cancer.
Pinto AE; André S; Pereira T; Silva G; Soares J
Pathobiology; 2006; 73(2):63-70. PubMed ID: 16943686
[TBL] [Abstract][Full Text] [Related]
15. DNA ploidy and pS2 protein expression in breast cancer.
Ioakim-Liossi A; Karakitsos P; Aroni K; Markopoulos C; Delivelioti K; Gogas J; Kyrkou K
Cytopathology; 1997 Jun; 8(3):171-6. PubMed ID: 9202892
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast.
Perin T; Canzonieri V; Massarut S; Bidoli E; Rossi C; Roncadin M; Carbone A
Eur J Cancer; 1996 Jun; 32A(7):1148-55. PubMed ID: 8758245
[TBL] [Abstract][Full Text] [Related]
17. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
[TBL] [Abstract][Full Text] [Related]
18. [DNA ploidy is an independent prognostic biomarker in breast invasive ductal carcinoma].
Pinto AE; Pereira T; Silva GL; Ferreira MC; André S
Acta Med Port; 2012; 25(6):399-407. PubMed ID: 23534591
[TBL] [Abstract][Full Text] [Related]
19. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.
Poller DN; Snead DR; Roberts EC; Galea M; Bell JA; Gilmour A; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1993 Jul; 68(1):156-61. PubMed ID: 8100443
[TBL] [Abstract][Full Text] [Related]
20. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
